30 / 49
The probability of experiencing a CNS
progression event, in the absence of
non-CNS progression or death, was
consistently lower with osimertinib
treatment than with SoC*
Conditional probability of CNS progression*, % (95% CI)
Osimertinib (n=61)
SoC (n=67)
At 6 months
5 (1, 13)
18 (10, 28)
At 12 months
8 (3, 16)
24 (15, 35)
Osimertinib
SoC
CNS progression
Non-CNS progression
Death
CNS progression
Non-CNS progression
Death
0.0
0.2
0.4
0.6
0.8
1.0
0
3
6
9
15
21
Probability
18
12
Time (months)
COMPETING RISK ANALYSIS: CNS FULL ANALYSIS SET
30
Presented by J Vansteenkiste at ESMO Asia 2017, 17–19 November 2017, Singapore
Proferred Paper Session 1, Abstract LBA5. Ann Oncol 2017;28 (suppl_10): mdx729.007